These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15541116)

  • 1. A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value.
    Shi XB; Gandour-Edwards R; Beckett LA; Deitch AD; de Vere White RW
    BJU Int; 2004 Nov; 94(7):996-1002. PubMed ID: 15541116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
    Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
    Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY.
    Watanabe J; Nishiyama H; Okubo K; Takahashi T; Toda Y; Habuchi T; Kakehi Y; Tada M; Ogawa O
    Urology; 2004 May; 63(5):989-93. PubMed ID: 15135005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer.
    Kaserer K; Schmaus J; Bethge U; Migschitz B; Fasching S; Walch A; Herbst F; Teleky B; Wrba F
    J Pathol; 2000 Mar; 190(4):450-6. PubMed ID: 10699994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors.
    Meyers FJ; Gumerlock PH; Chi SG; Borchers H; Deitch AD; deVere White RW
    Cancer; 1998 Dec; 83(12):2534-9. PubMed ID: 9874460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 gene alterations in prostate cancer after radiation failure and their association with clinical outcome: a molecular and immunohistochemical analysis.
    Rakozy C; Grignon DJ; Li Y; Gheiler E; Gururajanna B; Pontes JE; Sakr W; Wood DP; Sarkar FH
    Pathol Res Pract; 1999; 195(3):129-35. PubMed ID: 10220791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
    Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential.
    Navone NM; Labate ME; Troncoso P; Pisters LL; Conti CJ; von Eschenbach AC; Logothetis CJ
    J Urol; 1999 Jan; 161(1):304-8. PubMed ID: 10037428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 is mutated in a subset of advanced-stage prostate cancers.
    Bookstein R; MacGrogan D; Hilsenbeck SG; Sharkey F; Allred DC
    Cancer Res; 1993 Jul; 53(14):3369-73. PubMed ID: 8324747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers--investigation by temperature gradient gel electrophoresis (TGGE).
    Schlechte HH; Schnorr D; Löning T; Rudolph BD; Pohrt UM; Loening SA
    J Urol; 1997 Mar; 157(3):1049-53. PubMed ID: 9072541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response.
    Deissler H; Kafka A; Schuster E; Sauer G; Kreienberg R; Zeillinger R
    Oncol Rep; 2004 Jun; 11(6):1281-6. PubMed ID: 15138567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analyses of p53 mutations in breast cancers with a combined use of yeast functional assay and immunohistochemical staining].
    Takahashi M
    Hokkaido Igaku Zasshi; 1998 May; 73(3):275-86. PubMed ID: 9719952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 mutation in prostate needle biopsies--comparison with patients follow-up.
    Ecke TH; Schlechte HH; Hübsch A; Lenk SV; Schiemenz K; Rudolph BD; Miller K
    Anticancer Res; 2007; 27(6B):4143-8. PubMed ID: 18225585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of p53 mutations in Hong Kong colorectal carcinomas by conventional PCR-SSCP analysis versus p53 yeast functional assays.
    Leung CS; Lung ML
    Anticancer Res; 1999; 19(1A):625-8. PubMed ID: 10226610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and immunohistochemical analyses of p53 independently predict regional metastasis of gastric cancers.
    Shiao YH; Palli D; Caporaso NE; Alvord WG; Amorosi A; Nesi G; Saieva C; Masala G; Fraumeni JF; Rice JM
    Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):631-3. PubMed ID: 10868700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The p53 gene in soft tissue sarcomas: prognostic value of DNA sequencing versus immunohistochemistry.
    Taubert H; Würl P; Bache M; Meye A; Berger D; Holzhausen HJ; Hinze R; Schmidt H; Rath FW
    Anticancer Res; 1998; 18(1A):183-7. PubMed ID: 9568075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study.
    Salinas-Sánchez AS; Lorenzo-Romero JG; Giménez-Bachs JM; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-Del-Campo A; Hernández-Millán IR; Segura-Martín M; Atienzar-Tobarra M; Escribano-Martínez J
    Urol Oncol; 2008; 26(6):620-6. PubMed ID: 18367096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
    Abaza R; Diaz LK; Laskin WB; Pins MR
    J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of a yeast assay to detect functional p53 mutations in archival prostate cancer tissue.
    Shi XB; Di Mauro SM; Highshaw R; Deitch AD; Evans CP; Gumerlock PH; deVere White RW
    Cancer Biother Radiopharm; 2002 Dec; 17(6):657-64. PubMed ID: 12537669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate biopsy: who, how and when. An update.
    Djavan B; Milani S; Remzi M
    Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.